Alchemab Therapeutics
Uses AI over a database of antibodies from people unusually resistant to disease to find protective antibodies and their targets, then develops them as drugs; its first, ATLX-1282 for ALS, is licensed to Eli Lilly.
Money and evidence
No research by this company is on the record yet.
Rounds and research, on one timeline
- 2026-07-09Series A extensionRound
GBP 25M (the release gives $34M)
For: building its clinical pipeline and advancing more candidates into development, and growing its antibody database from 500 million to over a billion sequences
Toward the clinicData generation
The release names the British Business Bank as the sole investor, made through its commercial subsidiary British Patient Capital, and calls it the bank's largest life sciences investment. It brings the Series A to GBP 109M.
On the deal: Carmine Circelli (Senior Investment Director, Life Sciences; spoke for the bank in the announcement, British Business Bank); Charlotte Lawrence (Managing Director of Direct Equity; spoke for the bank in the announcement, British Business Bank)
- 2025-09-09Series A extensionRound
$32M
For: taking ATLX-2847, its own muscle-atrophy programme, into clinical development, moving earlier immune and neurological programmes toward the clinic, and expanding the platform
Toward the clinicModels and platform
Announced with the start of the Phase 1 study of ATLX-1282. The release calls Lilly's a strategic investment and puts the Series A at $114M to that date.
Ono Venture InvestmentEli LillyExisting investor · RA CapitalExisting investor · SV Health InvestorsExisting investor · DCVC BioExisting investor · Lightstone Ventures
Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.
Its investors also backed
Other companies on this page whose rounds name the same investor.
- British Business BankIneffable Intelligence